-
A Breakthrough in Diabetes Care: Afrezza Approved for Children and Adolescents
A New Chapter for Pediatric Diabetes Management For many families managing diabetes, the daily routine of injections can be a significant source of stress and discomfort. MannKind Corporation has recently reached a major milestone in diabetes treatment: the FDA has officially approved Afrezza (insulin human) inhalation powder for use in children and adolescents with diabetes.…
-
New NIH Research Paves the Way for Experimental Opioid Use Disorder Treatment
A Breakthrough in Addiction Research The National Institutes of Health (NIH) has announced a significant milestone in the fight against the opioid epidemic. Recent findings from the National Institute on Drug Abuse (NIDA) have cleared the path for a new clinical trial focused on evaluating an experimental treatment for opioid use disorder (OUD). Why This…
-
New Hope Against Resistant UTIs: FDA Approves Zaynich
A Breakthrough in Antibiotic Treatment The landscape for treating severe infections just got a new, powerful tool. The FDA has officially approved Zaynich, a combination antibiotic consisting of cefepime and zidebactam, designed specifically to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. Why This Approval Matters As antibiotic resistance continues to grow, healthcare…
-
A New Milestone in Melanoma Treatment: 5-Year Data for mRNA-4157 and Keytruda
Breaking Down the Long-Term Results In a significant development for oncology, Moderna and Merck have released updated 5-year follow-up data from the Phase 2b KEYNOTE-942 clinical trial. This study investigates the combination of mRNA-4157 (V940), an investigational individualized neoantigen therapy, alongside Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for patients with resected high-risk melanoma. What the Data…
-
Revolutionizing Medical Research: First Foundation Labs Partners with Microsoft
A New Era for Clinical Discovery The landscape of medical research is undergoing a significant transformation as First Foundation Labs, an initiative founded by the Luma Group, announces a strategic collaboration with Microsoft. By integrating AI-powered clinical and translational reasoning into the Microsoft Discovery platform, this partnership aims to accelerate how researchers approach complex medical…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-31-2026 TO 06-06-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$BYSI, $CGEM, $CING, $CRDF, $CUE, $EQ, $VOR, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 2026 Jefferies Global Healthcare Conference, biopharmaceutical, clinical-research, EULAR 2026 Congress (European Congress of Rheumatology), fda, new drug application, pr-newswire, press-releases, Webcast -
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
NYSEAMERICAN: $ATNM Source: Read More
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-24-2026 TO 05-30-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-17-2026 TO 05-23-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$CGON, $CRBP, $FATE, $NBP, $NMRA, $TNXP, $VTGN, $ZNTL, A.G.P.’s Annual Virtual Healthcare Conference, biopharmaceutical, clinical-research, fda, H.C. Wainwright 4th Annual BioConnect Investor Conference, ISPOR 2026, new drug application, pr-newswire, press-releases, RBC Capital Markets Global Healthcare Conference, Stifel 2026 Virtual Oncology Forum -
Compass Therapeutics (CMPX) enters the second half of 2026 in a strong financial position
NASDAQ: $CMPX Compass Therapeutics enters the second half of 2026 in a strong financial position, though its stock has recently experienced significant volatility following the long-awaited data readout for its lead program. Cash Runway As of the most recent financial updates in early 2026, Compass Therapeutics is exceptionally well-capitalized for a clinical-stage biotech: 2026 Pipeline…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-03-2026 TO 05-09-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
Beyond the Growth Chart: New Long-Term Data on VOXZOGO® for Achondroplasia
NASDAQ: $BMRN The landscape of pediatric endocrinology is shifting. At the Pediatric Endocrine Society’s (PES) 2026 Annual Meeting in San Francisco, new data presented by BioMarin Pharmaceutical Inc. has provided a clearer picture of how long-term treatment with VOXZOGO® (vosoritide) impacts children with achondroplasia. While height is often the most visible metric in skeletal dysplasias,…
-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…